TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

GIAZO

BALSALAZIDE DISODIUM
Approved 2012-02-03
1
Indication
--
Phase 3 Trials
14
Years on Market

Details

Status
Discontinued
First Approved
2012-02-03
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: BALSALAZIDE DISODIUM

GIAZO Approval History

Loading approval history...

What GIAZO Treats

1 FDA approvals

Originally approved for its first indication in 2012 .

  • Other (1)
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

GIAZO FDA Label Details

Pro

GIAZO Patents & Exclusivity

Latest Patent: Jun 2031

Patents (4 active)

US8497256 Expires Jun 23, 2031
US7452872 Expires Aug 24, 2026
US7625884 Expires Aug 24, 2026
US9192616 Expires Aug 2, 2026
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.